OncLive TV

Elena Elimova, MD, discusses the efficacy of zanidatamab with chemotherapy in HER2-positive advanced gastroesophageal adenocarcinoma.

Alexander Chehrazi-Raffle, MD, details safety data and the clinical implications of an analysis of second-line tivozanib for patients with metastatic RCC.

Amir Fathi, MD, discusses findings with ziftomenib in patients with relapsed/refractory, NPM1-mutant acute myeloid leukemia as demonstrated in KOMET-001.

Johannes Schetelig, MD, discusses outcomes with haploidentical related vs mismatched unrelated donor transplantation in high-risk AML, ALL, and MDS.

Saurabh Dahiya, MD, FACP, discusses safety and efficacy data from a study of the CAR T-cell therapy KITE-363 in relapsed/refractory B-cell lymphoma.

Deena M. Atieh Graham, MD, discusses notable shifts within the ovarian cancer landscape leading to better patient outcomes.

Douglas R. Adkins, MD, discusses the FDA approval of pembrolizumab for neoadjuvant and adjuvant treatment in resectable, locally advanced head and neck squamous cell carcinoma.

Guru P. Sonpavde, MD, discusses nivolumab plus ipilimumab in treatment-naive unresectable or metastatic urothelial carcinoma.

Tomasz Jankowski, MD, PhD, discusses THIO sequenced with cemiplimab for the third-line treatment of patients with ICI-resistant advanced NSCLC.

David J. Benjamin, MD, expands on real-world studies to help contextualize clinical trial data and inform treatment decisions in urothelial cancer.

Dickon Hayne, MD, FRCS, MBBS, discusses the use of mitomycin plus BCG as a potential alternative to BCG alone in non–muscle-invasive bladder cancer.

William C. Huang, MD, details the FDA approval of intravesical mitomycin for recurrent, low-grade, intermediate-risk non–muscle invasive bladder cancer.

Tetiana Skrypets, MD, PhD, discusses next steps for researching the clinical features and treatment outcomes of older patients with PTCL.

Martin E. Gutierrez, MD, discusses data for Dato-DXd plus rilvegostomig in advanced or metastatic NSCLC.

Naval G. Daver, MD, highlights the efficacy of revumenib for the treatment of patients with NPM1-mutant relapsed/refractory acute myeloid leukemia.

Miguel Gonzalez Velez, MD, discusses the role of tarlatamab as a second-line treatment for small cell lung cancer.

Nathan A. Pennell, MD, PhD, discusses the significance of the FDA approval of taletrectinib for ROS1-positive non-small cell lung cancer.

Joshua Sabari, MD, explains the rationale behind targeting c-MET in nonsquamous EGFR wild-type advanced NSCLC.

Li Zhang, MD, discusses sacituzumab tirumotecan in patients with previously treated, advanced EGFR-mutated non–small cell lung cancer.

Kevin Kalinsky, MD, MS, FASCO, discusses potential new roles for the CLEOPATRA and DESTINY-Breast09 regimens in the HER2-positive breast cancer paradigm.

Massimo Cristofanilli, MD, details the implications of serial ESR1 mutation monitoring using ctDNA in HR-positive/HER2-negative advanced breast cancer.

Erica L. Mayer, MD, MPH, discusses the use of imlunestrant in HR+, HER2-negative advanced breast cancer following prior endocrine therapy.

Kevin Kalinsky, MD, discusses the importance of biomarker testing in guiding therapeutic decision-making in HR-positive, HER2-negative breast cancer.

Kevin Kalinsky, MD, MS, FASCO, discusses data with camizestrant plus a CDK4/6 inhibitor in ER–positive, HER2-negative advanced breast cancer.

Martin Wermke, MD, discusses obrixtamig in combination with topotecan for the treatment of patients with advanced small cell lung cancer.

Bogdana Schmidt, MD, MPH, discusses the role of minimally invasive and robotic strategies for the treatment of patients with bladder cancer.

Hope S. Rugo, MD, discusses quality of life data from the phase 3 SERENA-6 study.

Jason Luke, MD, discusses IMA203 vs investigator’s choice of standard therapy in patients with previously treated advanced cutaneous melanoma.

Hope Rugo, MD, discusses the application of findings from the DESTINY-Breast09 trial of T-DXd plus pertuzumab in HER2-positive breast cancer.

Hope Rugo, MD, discusses the evolving use of antibody-drug conjugates in HER2-positive breast cancer.